{"denoms":[{"counts":[{"groupId":"BG000","value":"403"},{"groupId":"BG001","value":"137"},{"groupId":"BG002","value":"136"},{"groupId":"BG003","value":"676"}],"units":"Participants"}],"groups":[{"description":"Ipilimumab was administered at a dosage of 3 mg/kg as an intravenous (IV) infusion administered over 90 minutes every 3 weeks for a total of 4 doses, together with gp100. Gp100 consisted of 2 separate peptide components: Peptide A, a peptide with sequence YLEPGPVTV (gp100:280-288\\[288V\\]) and Peptide B, a peptide with the sequence IMDQVPFSV (gp100:209-217\\[210M\\]). Each peptide was prepared with Montanide ISA-51. One dose of gp100 consisted of the administration of Peptide A, at a dosage of 2 mL or 1 mg, and Peptide B, at a dosage of 2 mL or 1 mg. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.","id":"BG000","title":"Ipilimumab Plus gp100"},{"description":"Ipilimumab was administered at a dosage of 3 mg/kg as an intravenous (IV) infusion administered over 90 minutes every 3 weeks for a total of 4 doses, together with matching vaccine placebo. The vaccine placebo consisted of sterile 0.9% sodium chloride. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.","id":"BG001","title":"Ipilimumab Monotherapy"},{"description":"Gp100 consisted of 2 separate peptide components: Peptide A, a peptide with sequence YLEPGPVTV (gp100:280-288\\[288V\\]) and Peptide B, a peptide with the sequence IMDQVPFSV (gp100:209-217\\[210M\\]). Each peptide was prepared with Montanide ISA-51. One dose of gp100 consisted of the administration of Peptide A, at a dosage of 2 mL or 1 mg, and Peptide B, at a dosage of 2 mL or 1 mg. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.","id":"BG002","title":"gp100"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"24","upperLimit":"84","value":"55.6"},{"groupId":"BG001","lowerLimit":"19","upperLimit":"88","value":"56.8"},{"groupId":"BG002","lowerLimit":"23","upperLimit":"90","value":"57.4"},{"groupId":"BG003","lowerLimit":"19","upperLimit":"90","value":"56.2"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"291"},{"groupId":"BG001","value":"95"},{"groupId":"BG002","value":"94"},{"groupId":"BG003","value":"480"}]}],"title":"< 65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"112"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"42"},{"groupId":"BG003","value":"196"}]}],"title":">=65 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"156"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"63"},{"groupId":"BG003","value":"275"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"81"},{"groupId":"BG002","value":"73"},{"groupId":"BG003","value":"401"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"380"},{"groupId":"BG001","value":"129"},{"groupId":"BG002","value":"129"},{"groupId":"BG003","value":"638"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"5"}]}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"30"}]}],"title":"Hispanic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0.2","upperLimit":"38.9","value":"5.09"},{"groupId":"BG001","lowerLimit":"-0.0","upperLimit":"35.9","value":"4.34"},{"groupId":"BG002","lowerLimit":"0.3","upperLimit":"31.2","value":"5.65"},{"groupId":"BG003","lowerLimit":"-0.0","upperLimit":"38.9","value":"5.05"}]}]}],"description":"Duration of melanoma is the number of years from date of initial diagnosis to the date of randomization. The randomization of 1 participant in the ipilumumab monotherapy cohort was prior to the initial diagnostic date. Data for 2 participants in the ipilimumab + gp100 cohort were missing.","dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Duration of Melanoma","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"10"}]}],"title":"M0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"62"}]}],"title":"M1a"},{"categories":[{"measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"121"}]}],"title":"M1b"},{"categories":[{"measurements":[{"groupId":"BG000","value":"285"},{"groupId":"BG001","value":"100"},{"groupId":"BG002","value":"98"},{"groupId":"BG003","value":"483"}]}],"title":"M1c"}],"description":"The \"M\" in the TNM (tumor, node, metastasis) system refers to distant metastases-whether, and how far, the cancer has spread outside the original site. M0: There is no evidence that the cancer has spread beyond the original site. M1: The cancer has spread beyond the original site. M1a: The cancer has spread to other areas of skin, underneath the epidermis to the dermis (subcutaneous), or to lymph node(s). M1b: The cancer has spread to the lung(s) only. M1c: The cancer has spread to other organs and/or locations in the body with or without elevated LDH.","paramType":"NUMBER","title":"Melanoma Stage","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"314"},{"groupId":"BG001","value":"105"},{"groupId":"BG002","value":"103"},{"groupId":"BG003","value":"522"}]}],"title":"No"},{"categories":[{"measurements":[{"groupId":"BG000","value":"89"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"33"},{"groupId":"BG003","value":"154"}]}],"title":"Yes"}],"paramType":"NUMBER","title":"Prior Interleukin-2 Therapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"149"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"254"}]}],"title":">upper limit of normal (ULN)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"252"},{"groupId":"BG001","value":"84"},{"groupId":"BG002","value":"81"},{"groupId":"BG003","value":"417"}]}],"title":"<=ULN"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"5"}]}],"title":"unknown"}],"description":"Upper limit of normal (ULN) was 250 U/L for most assessments (some variation caused by tests performed at local laboratories).","paramType":"NUMBER","title":"Lactate Dehydrogenase","unitOfMeasure":"Participants"}]}